Related Experiment Video
Updated: May 26, 2026
Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
Published on: April 15, 2016
Construction of an oncolytic herpes simplex virus that precisely targets hepatocellular carcinoma cells
Xinping Fu1, Armando Rivera, Lihua Tao
1Department of Biology and Biochemistry, Center for Nuclear Receptors and Cell Signaling, University of Houston, Houston, Texas 77204, USA.
Abstract:
Selective replication in tumor cells is a highly desirable feature for oncolytic viruses. Recent studies have shown that microRNAs (miRNAs) play important roles in controlling gene expression, and that certain tissue-specific miRNAs are frequently downregulated in malignant cells. miR-122 is a liver-specific microRNA. It is abundantly expressed in normal hepatocytes but is absent in many hepatocellular carcinoma (HCC) cells. We hypothesized that expression of an essential viral gene by a liver-specific promoter would initially restrict virus replication to cells of hepatic origin and that adding miR-122 complementary sequences to the viral gene would make the transcripts degradable by miR-122 in normal hepatocytes, thus further confining its replication to HCC. We have constructed such an oncolytic herpes simplex virus by linking the essential viral glycoprotein H gene with the liver-specific apolipoprotein E (apoE)-AAT promoter and by adding the miR-122a complimentary sequence to the 3' untranslated region (3'UTR). To further increase the safety of this virus, complementary sequences from miR-124a and let-7 were also engineered into the same 3'UTR. Designated liver-cancer specific oncolytic virus (LCSOV), it was highly selective in killing HCC cells and in shrinking HCC xenografts. We conclude that LCSOV is a highly specific oncolytic virus that can precisely target HCC.
Insights
This study engineered a liver-cancer specific oncolytic virus (LCSOV) that selectively targets hepatocellular carcinoma (HCC) cells. LCSOV utilizes microRNA-122 targeting for enhanced specificity, offering a promising new therapy for liver cancer.
Area of Science:
- Oncolytic virology
- Molecular oncology
- Gene therapy
Background:
- Oncolytic viruses offer a promising strategy for cancer treatment by selectively replicating within tumor cells.
- MicroRNAs (miRNAs) are key regulators of gene expression, with some tissue-specific miRNAs downregulated in cancers.
- Hepatocellular carcinoma (HCC) often lacks the liver-specific microRNA, miR-122, which is abundant in normal hepatocytes.
Purpose of the Study:
- To develop a novel oncolytic virus with enhanced specificity for hepatocellular carcinoma (HCC).
- To engineer a herpes simplex virus (HSV) that leverages liver-specific promoters and miRNA targeting for selective tumor cell killing.
- To improve the safety profile of oncolytic viruses through multi-miRNA complementary sequence integration.
Main Methods:
- Constructed a liver-cancer specific oncolytic virus (LCSOV) by linking an essential viral gene (glycoprotein H) to a liver-specific promoter (apoE-AAT).
- Engineered the 3' untranslated region (3'UTR) of the viral gene to include sequences complementary to miR-122a, miR-124a, and let-7.
- Evaluated the in vitro and in vivo efficacy and specificity of LCSOV against HCC cells and xenografts.
Main Results:
- LCSOV demonstrated highly selective replication and killing of HCC cells in vitro.
- Administration of LCSOV led to significant shrinkage of HCC xenografts in vivo.
- The engineered miRNA complementary sequences enhanced the tumor-targeting capabilities of the oncolytic virus.
Conclusions:
- LCSOV is a highly specific oncolytic virus precisely targeting hepatocellular carcinoma (HCC).
- The combination of liver-specific promoters and miRNA targeting represents an effective strategy for enhancing oncolytic virus safety and efficacy.
- This engineered virus holds potential as a targeted therapy for liver cancer.
